SAGE Therapeutics (SAGE) Tops Q4 EPS by $18.54, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St mixed as benchmark Treasury yields reach 5%, oil takes a pause
- Oil slides following outreach to Iran to limit Houthis actions in Red Sea
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Sage Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress
February 24, 2021 6:30 AM ESTReported positive interim data from Phase 3 open-label SHORELINE Study showing that more than 70% of patients successfully treated with zuranolone 30 mg needed two or fewer treatment courses over one year
Progressed WATERFALL Study now closed to enrollment investigating zuranolone for as needed treatment of major depressive disorder with data anticipated in the first half of 2021
Entered into global collaboration with Biogen worth up to $3.1 billion, enabling planned expansion and acceleration of the Sage pipeline and increasing the potential patient reach to more than 450 million, if successful
... More